Varicella-Zoster Virus IgM Control Serum BC104M

$94.00

Summary

Virion/Serion Diagnostic Kit Control for research use (RUO)
Varicella-Zoster Virus IgM Control Serum
Applications: ELISA
IgM control serum
Ready-to-use; pre-diluted for SERION ELISA classic and SERION ELISA antigen assays
3 mL

SKU: BC104M Categories: control serum, Virion/Serion kits Tags: ELISA control serum, IgM, Varicella-Zoster Virus

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Varicella-Zoster Virus reactive IgM
species reactivity	Varicella-Zoster Virus
applications	ELISA
assay type	Indirect & quantitative
available size	3 mL

Varicella-Zoster Virus IgM Control Serum BC104M

kit
Research area Infectious Disease
Storage Store at 2-8°C.
Associated products Varicella Zoster Virus (VZV) Envelope Glycoprotein E Control Antigen (BA104R02) Varicella-Zoster Virus Antigen (BA104VS) Varicella-Zoster Virus Glycoprotein Antigen (BA104VSG) Varicella-Zoster Virus IgA Control Serum (BC104A) Varicella-Zoster Virus IgG Control Serum (BC104G) Varicella-Zoster Virus IgM Control Serum (BC104M) Varicella-Zoster Virus IgA ELISA Kit (ESR104A) Varicella-Zoster Virus IgG ELISA Kit (ESR104G) Varicella-Zoster Virus IgM ELISA Kit (ESR104M)

target relevance

human antibody anti-Varicella-ZosterVirus

Varicella-ZosterVirus

Description
Virus that causes chickenpox (varicella) and shingles (herpes zoster)

Structure
Varicella-zoster virus (VZV), also known as Human herpesvirus 3 (HHV-3), is an enveloped, double-stranded DNA virus belonging to the genus Varicellovirus within the family Herpesviridae. The viral genome is enclosed within an icosahedral capsid surrounded by a protein tegument and a lipid envelope containing multiple glycoproteins that mediate host cell attachment and entry. Humans are the only known natural reservoir of the virus. Primary infection results in varicella (chickenpox), after which the virus establishes lifelong latency within sensory nerve ganglia. Reactivation of latent virus later in life results in herpes zoster (shingles). Varicella-zoster virus is highly contagious and spreads primarily through respiratory droplets, aerosolized virus from skin lesions, and direct contact with vesicular fluid.

Diagnosis
The diagnosis of varicella-zoster virus infection is performed through clinical evaluation, molecular testing, and serological methods. Polymerase chain reaction (PCR) is the preferred laboratory method due to its high sensitivity and specificity and can detect VZV DNA in vesicular fluid, lesion swabs, cerebrospinal fluid, blood, and tissue specimens. Direct fluorescent antibody testing and viral culture may also be used but are less sensitive than PCR. Serological assays, including ELISA-based tests, can detect VZV-specific IgM and IgG antibodies and are useful for determining immune status, previous exposure, or vaccine response. Laboratory confirmation is particularly important in atypical cases, immunocompromised patients, and individuals with suspected neurological complications.

Symptoms
Primary infection with varicella-zoster virus typically develops after an incubation period of approximately ten to twenty-one days and presents as chickenpox, characterized by fever, malaise, headache, and a generalized pruritic vesicular rash that progresses through macular, papular, vesicular, and crusting stages. Following recovery, the virus remains latent in sensory ganglia and may reactivate years or decades later as shingles. Herpes zoster is characterized by painful, unilateral vesicular eruptions distributed along affected dermatomes and is often preceded by burning, tingling, or localized pain. Complications of VZV infection include secondary bacterial skin infections, pneumonia, encephalitis, meningitis, cerebellitis, vision-threatening ophthalmic zoster, and postherpetic neuralgia, a chronic pain syndrome that may persist long after skin lesions have resolved. Severe disease is more common in elderly individuals, pregnant women, newborns, and immunocompromised patients.

Data

FAQ & Publications

Frequently Asked Questions

What is the intended application for the Varicella-Zoster Virus IgM Control Serum BC104M?

The Varicella-Zoster Virus IgM Control Serum BC104M is designed for use as a control serum in ELISA applications, specifically for SERION ELISA classic and SERION ELISA antigen assays to detect Varicella-Zoster Virus reactive IgM antibodies.

How should the Varicella-Zoster Virus IgM Control Serum BC104M be stored to maintain its stability?

The Varicella-Zoster Virus IgM Control Serum BC104M should be stored at 2-8°C to preserve its stability and usability for research applications.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.

Protocols

relevant to this product
BC104M protocol

Documents

#
CP0013	Safety Data Sheet	QC certificate

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Varicella-Zoster Virus IgM Control Serum BC104M

Data

FAQ & Publications

Protocols

Documents

Related Technical Resources & Posts

Reviews

Related Products

Enterovirus IgM Control Serum BC133M

Candida albicans IgM Control Serum BC117M

Influenza B Virus IgM Control Serum BC1232M

Campylobacter jejuni IgM Control Serum BC139M

Influenza A Virus IgM Control Serum BC1231M

Brucella IgM Control Serum BC116M

Helicobacter pylori IgM Control Serum BC118M

Borrelia burgdorferi IgM Control Serum BC121M

Aspergillus fumigatus IgM Control Serum BC132M

Echovirus IgM Control Serum BC135M

Cytomegalovirus IgM Control Serum BC109M

Coxsackie IgM Virus Control Serum BC134M

Coxiella burnetii Phase 2 IgM Control Serum BC1312M

Chlamydia trachomatis IgM Control Serum BC1372M

Chlamydia pneumoniae IgM Control Serum BC1371M